Using Implementation Science to Increase Pre-Exposure Prophylaxis Uptake Among African American Women

Pre-exposure prophylaxis may be a viable option for African American women at-risk for HIV infection, but few studies have identified optimal strategies to reach African American women in need of Pre-Exposure Prophylaxis nor examined effective strategies to scale-up Pre-Exposure Prophylaxis among African American women in the South. African American women in the South experience high rates of intimate partner violence which could force women to choose between HIV prevention or intimate partner violence prevention. The proposed research study seeks to develop, pilot-test, and evaluate a Pre-Exposure Prophylaxis Implementation Toolkit within two community healthcare clinics located in Jackson, Mississippi to increase Pre-Exposure Prophylaxis uptake among African American, address intimate partner violence as a barrier to Pre-Exposure Prophylaxis uptake, and ultimately combat racial disparities in women's HIV diagnoses.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

HIV and intimate partner violence are intersecting, mutually-reinforcing epidemics that significantly affect African American women, particularly women in the U.S. South. African American women face some of the highest rates of both HIV and intimate partner violence among U.S. women, and these burdens are most pronounced in the South. African American surviving intimate partner violence may experience forced, condom less sex, which increases the risk of HIV acquisition. Pre-exposure prophylaxis has the potential to be the most innovative HIV prevention strategy, however it remains underutilized by African American women and residents of the South. In order to reduce African American women's HIV acquisition risk in the South, effective HIV prevention interventions need to concurrently address relationship safety and HIV acquisition risks. Developing effective interventions to tackle this HIV-related disparity among African American women is essential to reach national HIV goals.Therefore, the proposed research aims to develop, test, and evaluate a Pre-Exposure Prophylaxis Implementation Toolkit for clinical staff in community healthcare settings in the South. The Toolkit will be evaluated using the Reach, Effectiveness-Adoption, Implementation, Maintenance (RE-AIM). The Toolkit will serve the dual purpose of increasing Pre-Exposure Prophylaxis uptake among African American women in the South while addressing intimate partner violence as a potential Pre-Exposure Prophylaxis barrier. This research project will include a formative evaluation (i.e., reach stage), including key informant interviews with clinical staff at the partnering community healthcare clinics (N=10), and six focus groups with African American women at risk for HIV acquisition (i.e., Pre-Exposure Prophylaxis-eligible; %50 intimate partner violence-exposed). The qualitative data from the formal evaluation will inform the development of the Pre-Exposure Prophylaxis Implementation Toolkit, including detailed curriculum and supporting materials. The Toolkit will be pilot tested in two community healthcare clinics using a nonrandomized waitlist control design employed at the clinic-level. Clinic 1 will receive the Toolkit; and after the 8-month data is collected, Clinic 2 will receive the Toolkit. Changes in Pre-Exposure Prophylaxis uptake and retention in care will be assessed at the clinic level from 8-months before and after the Toolkit is implemented (i.e., effectiveness stage). To examine these effects at the clinic-level, a series of interrupted time series analyses will be conducted. This approach allows us to analyze population changes as opposed to individual change. To yield a moderate effect size with a power=.80 and alpha =.05, a sample size of at least 8 timepoints are needed. Following the Toolkit's implementation, four focus groups with clinical staff will be conducted to assess barriers and facilitators (i.e., adoption stage). Lastly, key informant interviews with clinical staff (N=20) will be conducted to assess fidelity of the Toolkit's components.

Study Type

Interventional

Enrollment (Actual)

27

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Maryland
      • Baltimore, Maryland, United States, 21220
        • Johns Hopkins Bloomberg School of Public Health

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

- currently providing care at a community healthcare clinic in Mississippi

Exclusion Criteria:

  • non-English speaking
  • inability to read and comprehend questions

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Trauma-Informed Pre-Exposure Prophylaxis Implementation Toolkit
The Toolkit to be developed in the proposed study includes components from the women-specific Pre-Exposure Prophylaxis care continuum theoretical model and implementation challenges, and is adapted to identify and provide care to women experiencing intimate partner violence. Overall, the Toolkit is designed to create culturally-congruent, intimate partner violence-informed clinical settings; and equip clinical staff with the knowledge and skills they need to address HIV prevention for African American women; and integrate intimate partner violence into Pre-Exposure Prophylaxis care services.
Staff in this intervention will be trained to conducting intimate partner violence screening, and providing support to women through referrals to local community resources; to help African American women identify and understand HIV risk factors (e.g., unprotected condom less sex with a male partner who is HIV-positive or unknown HIV status); and to communicate with their African American women patients in a respectful way in order to build trust and facilitate shared decision making.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinic's proportion of women with Pre-Exposure Prophylaxis uptake
Time Frame: Baseline to 8-months after Toolkit implementation in each clinic

Pre-Exposure Prophylaxis uptake will be classified as a woman receiving a Pre-Exposure Prophylaxis prescription from a pharmacy.

Pre-Exposure Prophylaxis uptake will be coded as a binary variable (0=did not receive Pre-Exposure Prophylaxis prescription; 1=received Pre-Exposure Prophylaxis prescription) and will be obtained from clinic aggregated data.

Baseline to 8-months after Toolkit implementation in each clinic

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinic's proportion of women with Pre-Exposure Prophylaxis retention
Time Frame: Baseline to 8-months after Toolkit implementation in each clinic
Pre-Exposure Prophylaxis retention will be classified as a woman attending scheduled three- and six-month followup visits. There will be a three and six-month follow-up visit variable and coded as binary (0=did not attend follow-up visit; 1= did attend follow-up visit).
Baseline to 8-months after Toolkit implementation in each clinic
Clinic's %Pre-Exposure Prophylaxis Uptake
Time Frame: Baseline to 8-months after Toolkit implementation in each clinic
% Pre-Exposure Prophylaxis Uptake is calculated as the number of African American women who initiated Pre-Exposure Prophylaxis divided by the number of African American women who were offered Pre-Exposure Prophylaxis at the clinic.
Baseline to 8-months after Toolkit implementation in each clinic
Clinic's Pre-Exposure Prophylaxis Coverage
Time Frame: Baseline to 8-months after Toolkit implementation in each clinic
% Pre-Exposure Prophylaxis Coverage will be calculated as the number of African American women using Pre-Exposure Prophylaxis divided by the number of African American women who visited the clinic.
Baseline to 8-months after Toolkit implementation in each clinic

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Tiara C. Willie, PhD, Johns Hopkins Bloomberg School of Public Health

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 31, 2021

Primary Completion (Actual)

June 28, 2025

Study Completion (Actual)

September 22, 2025

Study Registration Dates

First Submitted

November 17, 2021

First Submitted That Met QC Criteria

November 17, 2021

First Posted (Actual)

December 1, 2021

Study Record Updates

Last Update Posted (Actual)

March 17, 2026

Last Update Submitted That Met QC Criteria

March 16, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe